Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction

World Journal of Urology

Volumn 28, Issue 1, 2010, Pages 17-22

  Tuncel, Altug ^a   Nalcacioglu, Varol ^a   Ener, Kemal ^a   Aslan, Yilmaz ^a   Aydin, Omur ^a   Atan, Ali ^a  

^a MINISTRY OF HEALTH   (Turkey)

Author keywords

Benign prostate hyperplasia; Erectile dysfunction; Lower urinary tract symptoms; Sildenafil citrate; Tamsulosin

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SILDENAFIL; SULFONAMIDE; SULFONE; TAMSULOSIN;

AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; ERECTILE DYSFUNCTION; HUMAN; MALE; MIDDLE AGED; PROSTATISM; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; DRUG THERAPY, COMBINATION; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PROSTATISM; PURINES; SULFONAMIDES; SULFONES;

EID: 75849116360     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-009-0484-z     Document Type: Article

References (29)

1. Reynard JM, Peters TJ, Lamond E, Abrams P (1995) The significance of abdominal straining in men with lower urinary tract symptoms. Br J Urol 75: 148-153.
2. Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, Lieber MM (1997) Natural history of prostatism: risk factors for acute urinary retention. J Urol 158: 481-487.
3. Norman RW, Nickel JC, Fish D, Pickett SN (1994) 'Prostate-related symptoms' in Canadian men 50 years of age or older: prevalence and relationships among symptoms. Br J Urol 74: 542-550.
4. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB (1994) Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151: 54-61.
5. Girman CJ, Jacobsen SJ, Tsukamato T, Richard F, Garraway WM, Sagnier PP, Guess HA, Rhodes T, Boyle P, Lieber MM (1998) Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 51: 428-436.
6. Baniel J, Israilov S, Shmueli J, Segenreich H, Livne PM (2000) Sexual function in 131 patients with benign prostatic hyperplasia before prostatectomy. Eur Urol 38: 53-58.
7. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U (2000) Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res 12: 305-311.
8. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, O'Leary MP, Puppo P, Robertson C, Giuliano F (2003) Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 44: 637-649.
9. Elliott SP, Gulati M, Pasta DJ, Spitalny GM, Kane CJ, Yee R, Lue TF (2004) Obstructive lower urinary tract symptoms correlate with erectile dysfunction. Urology 63: 1148-1152.
10. Kaplan AS, Gonzales RR (2007) Phosphodiesterase type 5 inhibitors fort he treatment of male lower urinary tract symptoms. Rev Urol 9: 73-77.
11. Namasivayam S, Minhas S, Brooke J, Joyce AD, Prescott S, Eardley I (1998) The evaluation of sexual function in men presenting with benign prostatic hyperplasia. Br J Urol 82: 842-846.
12. Roehrborn CG (2008) Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Rev Urol 10: 14-25.
13. Kaminetsky JC (2006) Comorbid LUTS and erectile dysfunction: optimizing their management. Curr Med Res Opin 22: 2497-2506.
14. Andersson KE (2001) Physiology of penile erection. Pharmacol Rev 53: 417-450.
15. Becker AJ, Uckert S, Stief CG, Scheller F, Knapp WH, Hartmann U, Jonas U (2002) Cavernous and systemic plasma levels of norepinephrine and epinephrine during different penile conditions in healthy men and patients with erectile dysfunction. Urology 59: 281-286.
16. Traish AM, Kim NN, Goldstein I, Moreland RB (1999) Alpha-adrenergic receptors in the penis. Identification, characterization, and physiological function. J Androl 20: 671-682.
17. Francis SH, Blount MA, Zoraghi R, Corbin JD (2005) Molecular properties of mammalian proteins that interact with cGMP: protein kinases, cation channels, phosphodiesterase, and multi-drug anion transporters. Front Biosci 10: 2097-2117.
18. Uckert S, Kuthe A, Jonas U, Stief CG (2001) Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 166: 2484-2490.
19. Yassin A, Saad F, Hoesl CE, Traish AM, Hammadeh M, Shabsigh R (2006) Alpha-adrenoreceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS-implications for clinical practice. Andrologia 38: 1-12.
20. Andersson KE, Chapple CR, Hofner K (2002) Future drugs for he treatment of benign prostatic hyperplasia. World J Urol 19: 436-442.
21. Gradini R, Realacci M, Ginepri A, Naso G, Santangelo C, Cela O, Sale P, Berardi A, Petrangeli E, Gallucci M, Di Silverio F, Russo MA (1999) Nitric oxide synthases in normal and benign hyperplastic human prostate: immunohistochemistry and molecular biology. J Pathol 189: 224-229.
22. Bing W, Chang S, Hypolite JA, Di Santo ME, Zderic SA, Rolf L, Wein AJ, Chacko S (2003) Obstruction-induced changes in urinary bladder smooth muscle contractility: a role for Rho kinase. Am J Physiol Renal Physiol 285: F990-F997.
23. Deedwania PC (2003) Mechanisms of endothelial dysfunction in the metabolic syndrome. Curr Diabetes Rep 3: 289-292.
24. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L (2008) Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 180: 1228-1234.
25. McVary KT, Monnig W, Camps JL, Young JM, Tseng LJ, van den Ende G (2007) Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177: 1071-1077.
26. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E (2008) A randomised, placebo-controlled study to assess the efficacy o twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 53: 1236-1244.
27. Kaplan A, Gonzales RR, Te AE (2007) Combination of alfuzosin and sildenafil superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 51: 1717-1723.
28. Bechara A, Romano S, Casabe A, Haime S, Dedola P, Hernandez C, Rey H (2008) Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 5: 2170-2178.
29. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS (2007) Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 177: 1401-1407.